thanks for the reply macrae.i thought those questions would be a bit hard to answer..its no personal attack but if you feel so strongly against prr i just would like to find out why considering them posts of yours about eugene kopp being a director and ian frazer being of no use to prr when he was when you were a holder..some good debate is healthy for us holders to find out more but only if there is truth behind them..if you dont want to though its your right to not answer..thanks anyway and aprreciate you effort in answering my questions..one last one though if you could.
with your bioshares spec but class c statement..i cant seem to find that as in the last bioshares write up they have a wait as they say wait till ind status os given.and all past bioshares issues that i can find say spec buy class A.im sure prr have more than 1 product as you know with crypto being 1 that is being dicussed with a major pharma for jv...here it is..
Summary Prima Biomed looks to have found, after several tumultuous years, a stronger footing and a clearer focus, with the commercialisation of CVac its principle goal. The company also holds three other assets which it aims to divest. The CVac product warrants continued clinical investigation and the current treatment regimes for ovarian cancer are unsatisfactory. Prima Biomed is a stock to watch. However, we recommend that investors wait until the FDA 'approves' the company's IND application and full clinical trial protocol details are made available by the company. When that event occurs, a more timely and detailed assessment of the clinical and funding risks in front of the company can be made. Bioshares recommendation: Wait
PRR Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)